IDT Biologika GmbH, a developer of pharmaceutical technology and a producer of proprietary and third-party biopharmaceuticals and viral and bacterial vaccines, and Oncotec Pharma Produktion have reported investments to increase their production capacities. IDT will invest €40 million ($55 million) in its vaccine and parenteral sterile fill-and-finish capacities in syringes, vials, lyophilization, and packaging at its BioPharmaPark, located in Dessau-Roβlau, Germany. Among the upgrades are serialization and anti-counterfeiting capabilities designed to enable the authentication of finished pharmaceuticals.
In September 2013, IDT started up its new production capacity for sterile parenteral drug products, including vaccines and biologics, having completed an expansion project announced in 2011. Capacity to manufacture vial-based products in liquid and lyophilized form will increase to 60 million units per year. Oncotec Pharma Produktion GmbH, a pharmaceutical manufacturing partner of aseptically produced cytostatic drug products, will invest €30 million ($41 million) to expand sterile parenteral oncology drug manufacturing capacity within IDT’s BioPharmaPark. Manufacturing facilities and pharmaceutical site infrastructure will be enlarged over the next few years. The expansion projects are expected to be complete in 2016.
Source: IDT Biologika